These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 19854637)

  • 41. A general pharmacodynamic interaction model identifies perpetrators and victims in drug interactions.
    Wicha SG; Chen C; Clewe O; Simonsson USH
    Nat Commun; 2017 Dec; 8(1):2129. PubMed ID: 29242552
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mixture dynamics: Combination therapy in oncology.
    Gabrielsson J; Gibbons FD; Peletier LA
    Eur J Pharm Sci; 2016 Jun; 88():132-46. PubMed ID: 27050307
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Stability of additive treatment effects in multiple treatment comparison meta-analysis: a simulation study.
    Thorlund K; Mills E
    Clin Epidemiol; 2012; 4():75-85. PubMed ID: 22570567
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Accounting for dropout in xenografted tumour efficacy studies: integrated endpoint analysis, reduced bias and better use of animals.
    Martin EC; Aarons L; Yates JW
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):131-41. PubMed ID: 27220867
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A mechanistic assessment of the nature of pharmacodynamic drug-drug interaction in vivo and in vitro.
    Bisaso KR; Mukonzo JK; Ette EI
    In Silico Pharmacol; 2023; 11(1):31. PubMed ID: 37899968
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Additive Dose Response Models: Explicit Formulation and the Loewe Additivity Consistency Condition.
    Lederer S; Dijkstra TMH; Heskes T
    Front Pharmacol; 2018; 9():31. PubMed ID: 29467650
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Testing non-additivity (interaction) in two-way ANOVA tables with no replication.
    Alin A; Kurt S
    Stat Methods Med Res; 2006 Feb; 15(1):63-85. PubMed ID: 16477949
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin.
    Shah DK; Haddish-Berhane N; Betts A
    J Pharmacokinet Pharmacodyn; 2012 Dec; 39(6):643-59. PubMed ID: 23151991
    [TBL] [Abstract][Full Text] [Related]  

  • 49. On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach.
    Haddish-Berhane N; Shah DK; Ma D; Leal M; Gerber HP; Sapra P; Barton HA; Betts AM
    J Pharmacokinet Pharmacodyn; 2013 Oct; 40(5):557-71. PubMed ID: 23933716
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A predictive pharmacokinetic-pharmacodynamic model of tumor growth kinetics in xenograft mice after administration of anticancer agents given in combination.
    Terranova N; Germani M; Del Bene F; Magni P
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):471-82. PubMed ID: 23812004
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Translational pharmacokinetic-pharmacodynamic modeling from nonclinical to clinical development: a case study of anticancer drug, crizotinib.
    Yamazaki S
    AAPS J; 2013 Apr; 15(2):354-66. PubMed ID: 23250669
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Translational PK-PD/TD modeling of antitumor effects and peripheral neuropathy in gemcitabine and nab-paclitaxel chemotherapy from xenograft mice to patients for optimal dose and schedule.
    Kobuchi S; Morita A; Jonan S; Amagase K; Ito Y
    Cancer Chemother Pharmacol; 2024 Apr; 93(4):365-379. PubMed ID: 38117301
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Radius additivity score: a novel combination index for tumour growth inhibition in fixed-dose xenograft studies.
    Melillo N; Dickinson J; Tan L; Mistry HB; Huber HJ
    Front Pharmacol; 2023; 14():1272058. PubMed ID: 37900154
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Model-based prediction of effective target exposure for MEN1611 in combination with trastuzumab in HER2-positive advanced or metastatic breast cancer patients.
    Tosca EM; Borella E; Piana C; Bouchene S; Merlino G; Fiascarelli A; Mazzei P; Magni P
    CPT Pharmacometrics Syst Pharmacol; 2023 Nov; 12(11):1626-1639. PubMed ID: 36793223
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Modeling restoration of gefitinib efficacy by co-administration of MET inhibitors in an EGFR inhibitor-resistant NSCLC xenograft model: A tumor-in-host DEB-based approach.
    Tosca EM; Gauderat G; Fouliard S; Burbridge M; Chenel M; Magni P
    CPT Pharmacometrics Syst Pharmacol; 2021 Nov; 10(11):1396-1411. PubMed ID: 34708556
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A Novel Integrated Pharmacokinetic-Pharmacodynamic Model to Evaluate Combination Therapy and Determine
    Choi YH; Zhang C; Liu Z; Tu MJ; Yu AX; Yu AM
    J Pharmacol Exp Ther; 2021 Jun; 377(3):305-315. PubMed ID: 33712506
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Different ODE models of tumor growth can deliver similar results.
    Koziol JA; Falls TJ; Schnitzer JE
    BMC Cancer; 2020 Mar; 20(1):226. PubMed ID: 32183732
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Array of translational systems pharmacodynamic models of anti-cancer drugs.
    Ait-Oudhia S; Mager DE
    J Pharmacokinet Pharmacodyn; 2016 Dec; 43(6):549-565. PubMed ID: 27771815
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tumor Static Concentration Curves in Combination Therapy.
    Cardilin T; Almquist J; Jirstrand M; Sostelly A; Amendt C; El Bawab S; Gabrielsson J
    AAPS J; 2017 Mar; 19(2):456-467. PubMed ID: 27681102
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.